61 related articles for article (PubMed ID: 34408399)
1. Micafungin exerts antitumor effect on breast cancer and osteosarcoma through preventing EMT in tumor cells in an USP7/AKT/GSK-3β pathway-dependent manner.
Wang QL; Wang L; Li QY; Li HY; Lin L; Wei D; Xu JY; Luo XJ
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4447-4459. PubMed ID: 38108838
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment.
Wawrzyniak D; Grabowska M; Głodowicz P; Kuczyński K; Kuczyńska B; Fedoruk-Wyszomirska A; Rolle K
PLoS One; 2020; 15(8):e0237889. PubMed ID: 32817625
[TBL] [Abstract][Full Text] [Related]
3. Erianin inhibits tumor growth by promoting ferroptosis and inhibiting invasion in hepatocellular carcinoma through the JAK2/STAT3/SLC7A11 pathway.
Chen L; Sun R; Fang K
Pathol Int; 2024 Mar; 74(3):119-128. PubMed ID: 38240458
[TBL] [Abstract][Full Text] [Related]
4. NHF-derived carbon dots: prevalidation approach in breast cancer treatment.
Tiron CE; Luta G; Butura M; Zugun-Eloae F; Stan CS; Coroaba A; Ursu EL; Stanciu GD; Tiron A
Sci Rep; 2020 Jul; 10(1):12662. PubMed ID: 32728167
[TBL] [Abstract][Full Text] [Related]
5. Erianin promotes apoptosis and inhibits Akt-mediated aerobic glycolysis of cancer cells.
Han S; Chen S; Wang J; Huang S; Xiao Y; Deng G
J Cancer; 2024; 15(8):2380-2390. PubMed ID: 38495480
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein-mediated regulation of lipid metabolism induces distinctive effects in different types of breast cancer cells.
Ben Hassen C; Gutierrez-Pajares JL; Guimaraes C; Guibon R; Pinault M; Fromont G; Frank PG
Breast Cancer Res; 2020 Apr; 22(1):38. PubMed ID: 32321558
[TBL] [Abstract][Full Text] [Related]
7. (E)-2-Methoxy-4-(3-(4-Methoxyphenyl) Prop-1-en-1-yl) Phenol Suppresses Breast Cancer Progression by Dual-Regulating VEGFR2 and PPARγ.
Kim NY; Park HM; Lee HP; Hong JT; Yoon DY
J Microbiol Biotechnol; 2024 Feb; 34(2):240-248. PubMed ID: 37942548
[TBL] [Abstract][Full Text] [Related]
8. Nobiletin affects circadian rhythms and oncogenic characteristics in a cell-dependent manner.
Lellupitiyage Don SS; Robertson KL; Lin HH; Labriola C; Harrington ME; Taylor SR; Farkas ME
PLoS One; 2020; 15(7):e0236315. PubMed ID: 32706791
[TBL] [Abstract][Full Text] [Related]
9. Erianin inhibits the progression of triple-negative breast cancer by suppressing SRC-mediated cholesterol metabolism.
Li M; Kang S; Deng X; Li H; Zhao Y; Tang W; Sheng M
Cancer Cell Int; 2024 May; 24(1):166. PubMed ID: 38734640
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Erianin anti-triple negative breast cancer based on transcriptomics methods and network pharmacology.
Li M; Zhao Y; Li H; Kang S; Deng X; Sheng M
Aging (Albany NY); 2024 Feb; 16(3):2848-2865. PubMed ID: 38329441
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review).
Gao S; Liu S; Wei W; Qi Y; Meng F
Oncol Lett; 2023 Mar; 25(3):89. PubMed ID: 36817057
[TBL] [Abstract][Full Text] [Related]
12. Ecust004 Suppresses Breast Cancer Cell Growth, Invasion, and Migration via EMT Regulation.
Liu Z; Huang L; Sun L; Nie H; Liang Y; Huang J; Wu F; Hu X
Drug Des Devel Ther; 2021; 15():3451-3461. PubMed ID: 34408399
[TBL] [Abstract][Full Text] [Related]
13. Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Yang A; Li MY; Zhang ZH; Wang JY; Xing Y; Ri M; Jin CH; Xu GH; Piao LX; Jin HL; Zuo HX; Ma J; Jin X
J Ethnopharmacol; 2021 Jun; 273():113598. PubMed ID: 33220359
[TBL] [Abstract][Full Text] [Related]
14. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
15. Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer.
Sun Y; Li G; Zhou Q; Shao D; Lv J; Zhou J
Drug Des Devel Ther; 2020; 14():3301-3313. PubMed ID: 32848368
[TBL] [Abstract][Full Text] [Related]
16. Recent advances of antitumor leading compound Erianin: Mechanisms of action and structural modification.
Ma L; Li M; Zhang Y; Liu K
Eur J Med Chem; 2023 Dec; 261():115844. PubMed ID: 37804769
[TBL] [Abstract][Full Text] [Related]
17. Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of Erianin.
Wei X; Liu J; Xu Z; Wang D; Zhu Q; Chen Q; Xu W
Biomed Pharmacother; 2024 Apr; 173():116295. PubMed ID: 38401517
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
